Welcome to our dedicated page for Waystar Holding news (Ticker: WAY), a resource for investors and traders seeking the latest updates and insights on Waystar Holding stock.
Waystar Holding Corp. (Nasdaq: WAY) is a healthcare payment software company whose news flow centers on technology innovation, financial performance, and capital markets activity. As a provider of mission-critical, cloud-native software for healthcare payments, Waystar regularly issues updates about its AI capabilities, platform enhancements, and the impact of its solutions on revenue cycle operations for providers.
Readers of this news page can expect coverage of announcements related to Waystar AltitudeAI™, agentic intelligence, and the company’s broader vision for an autonomous revenue cycle. Recent communications have highlighted how Waystar’s AI-powered platform is used to prevent claim denials, accelerate denial appeals, improve reimbursement recovery, and reduce administrative workload across clinical documentation and billing workflows.
Waystar also reports quarterly and annual financial results, which are typically accompanied by earnings press releases and Form 8-K filings. These updates may include discussions of revenue trends, margins, key operating metrics, and guidance, as well as commentary from management on business performance. In addition, the company announces participation in investor conferences and presentations at major healthcare and technology events, reflecting its engagement with the investment community.
Corporate development and strategic transactions are another important theme in Waystar’s news. The company has announced the acquisition and integration of Iodine Software, describing how the combination of large clinical and financial datasets enhances its AI platform and expands its total addressable market. Index-related news, such as Waystar’s inclusion in the S&P SmallCap 600® Index, also appears in its releases.
For investors, analysts, and healthcare professionals, this news page provides a centralized view of Waystar’s product innovations, AI initiatives, financial disclosures, capital structure developments, and strategic milestones. Regular visits can help readers follow how the company’s software platform and data assets are evolving within the U.S. healthcare payment landscape.
Waystar (Nasdaq: WAY) announced that CEO Matt Hawkins and CFO Steve Oreskovich will participate in three investor conferences in early December 2025. Mr. Oreskovich will hold one-on-one meetings at the Evercore ISI HealthCONx on Dec 2, 2025 and will appear in a fireside chat at Citi's Global Healthcare Conference on Dec 3, 2025 at 1:45 p.m. ET, plus one-on-one meetings. Mr. Hawkins will appear in a fireside chat at Barclays 23rd Annual Global Technology Conference on Dec 10, 2025 at 3:40 p.m. PT and will conduct one-on-one meetings. Waystar will webcast the Citi and Barclays fireside chats and post recordings on its Investor Relations website.
Waystar (Nasdaq: WAY) announced it will join the S&P SmallCap 600, effective before market open on September 22, 2025. The company highlighted recent operating strength including double-digit revenue growth over the past 15 months, $1.8 trillion in gross claims processed annually, 115% net revenue retention, and scaled clients up to 15% year-over-year.
Waystar cited product innovation such as AltitudeAI, which the company says accelerates denial appeals 3x faster and boosts overturn rates by 40%+. Membership in the index is expected to broaden the shareholder base, increase institutional visibility, and enhance trading liquidity.
Waystar (Nasdaq: WAY) reported Q3 2025 revenue $268.7M, up 12% YoY, GAAP net income of $30.6M (diluted GAAP EPS $0.17) and non‑GAAP net income of $67.8M (non‑GAAP EPS $0.37).
Adjusted EBITDA was $112.7M with a 42% margin; cash flow from operations was $82M and unlevered free cash flow $96M. Net revenue retention was 113% and clients with >$100k LTM revenue rose 11% to 1,306.
Waystar raised full‑year 2025 guidance to $1.085–$1.093B revenue, adjusted EBITDA $451–$455M, and non‑GAAP net income $271–$274M.
RIS Rx (WAY) appointed John Driscoll as Chairman of the Board effective October 15, 2025. Driscoll is a veteran healthcare executive with leadership roles across payers, providers, and health‑tech platforms, including Executive Vice President and President, U.S. Healthcare at Walgreens Boots Alliance, nearly a decade as CEO of CareCentrix, and earlier roles at Castlight Health and Medco. He currently serves as Independent Chairman at Waystar (Nasdaq: WAY) and chairs the boards of UConn Health and Magnit Global. Management says Driscoll’s experience in scaling care‑at‑home and healthcare payment technology will support RIS Rx’s expansion and efforts to ensure patient financial support reaches patients.
Waystar (Nasdaq: WAY) will report third-quarter 2025 financial results for the period ended September 30, 2025 on Wednesday, October 29, 2025 after market close. The company will host a conference call at 4:30 p.m. Eastern Time the same day and provide a live audio webcast accessible from its investor relations website.
The webcast will be archived on the investor site for later access by investors and analysts.
Waystar (NASDAQ:WAY) has successfully completed its acquisition of Iodine Software, a strategic move that combines one of the industry's largest financial datasets with one of the largest clinical datasets. The acquisition expands Waystar's total addressable market by over 15% by adding Iodine's client base of more than 1,000 hospitals and health systems.
The deal is expected to be immediately accretive to gross margin and adjusted EBITDA margin, with positive impacts on revenue growth and non-GAAP net income per diluted share anticipated by 2027. The combination strengthens Waystar's AI-powered platform by integrating comprehensive clinical and financial intelligence, enhancing automation in healthcare revenue cycle management.
Waystar Holding Corp. (Nasdaq: WAY), a healthcare payment software provider, has been added to the S&P SmallCap 600® Index effective September 22, 2025. The company's platform serves over one million providers and processes more than $1.8 trillion in gross claims annually.
The company has demonstrated strong performance metrics, including a 115% net revenue retention and up to 15% year-over-year growth in scaled clients. Their AI innovation, Waystar AltitudeAI™, has shown significant results, accelerating denial appeals 3x faster and improving overturn rates by over 40%.
Waystar (Nasdaq: WAY) unveiled significant AI-powered innovations at its Fall Innovation Showcase to address major healthcare payment challenges. The company's AltitudeAI platform targets three critical issues: $20 billion in denial recovery costs, $17 billion in uncompensated care, and $2.6 billion in manual payer reimbursement inefficiencies.
The platform demonstrates impressive results, including 90% time savings across key capabilities, 40% more denial overturns for early adopters, and an increase in pre-service patient payments from 17% to 40%. For mid-size health systems, the solution reduces denial appeal processing time from 38 hours to 2 hours and cuts denial prevention work from 133 hours to under 6 hours.
EQT has completed a significant public offering of Waystar Holding Corp. (NASDAQ: WAY) common stock. The offering involved approximately 18.0 million shares, generating total proceeds of $705.8 million for all selling stockholders. EQT sold about 7.8 million shares for proceeds of $304.5 million, retaining approximately 24.9 million shares after the transaction.
The offering, underwritten by J.P. Morgan Securities LLC, was completed on September 12, 2025. Notably, Waystar Holding Corp. did not sell any shares in this offering and received no proceeds from the transaction.
Waystar (NASDAQ: WAY), a healthcare payments software provider, has announced the pricing of a secondary offering where existing shareholders will sell 18 million shares at $39.40 per share. The selling stockholders include investment funds from EQT AB, Bain Capital, LP, and Canada Pension Plan Investment Board.
The offering is expected to close around September 12, 2025, with J.P. Morgan acting as the underwriter. Importantly, Waystar will not receive any proceeds from this secondary offering as the company is not selling any shares directly.